This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 23/11/2110    most recent 01.ATV.0000090671.56682.D7v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khorana, A. A. Articles by Francis, C. W. Search for Related Content PubMed PubMed Citation Articles by Khorana, A. A. Articles by Francis, C. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Thinners Hazardous Substances DB HEPARIN Related Collections Platelet function inhibitors CV surgery: other

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:2110.)
© 2003 American Heart Association, Inc.

Thrombosis

Heparin Inhibition of Endothelial Cell Proliferation and Organization Is Dependent on Molecular Weight

Alok A. Khorana; Abha Sahni; Owen D. Altland; Charles W. Francis

From the James P. Wilmot Cancer Center and Hematology/Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY.

Correspondence to Charles W. Francis, MD, Hematology/Oncology Unit, Box 610, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642. E-mail charles_francis{at}urmc.rochester.edu

Objective— Studies have shown improved survival in cancer patients treated with low molecular weight heparins (LMWHs). Tumors depend on an expanding vasculature, and heparins may affect vessel growth and function. We investigated the effect of heparins differing in M_r on selected endothelial cell properties.

Methods and Results— Human umbilical vein endothelial cells were cultured with fibroblast growth factor-2 and heparins differing in M_r. Cell proliferation was assessed by [³H]thymidine incorporation, and vascular organization was assessed by in vitro assays. Maximum inhibition of 94±2% was observed with 6-kDa LMWH, greater than the inhibition seen with unfractionated heparin (58±8%) or 3-kDa LMWH (60±9%, P=0.02 for both). No inhibition of proliferation was observed with heparin tetrasaccharide, octasaccharide, or pentasaccharide (fondaparinux). Three- and 6-kDa fractions decreased endothelial tube formation in Matrigel to 58±15% and 67±9% (P<0.05), respectively, of that with fibroblast growth factor-2, whereas no inhibition was observed with unfractionated heparin, tetrasaccharide, pentasaccharide, or octasaccharide. LMWH (6 kDa) also inhibited vessel formation in a placental explant.

Conclusions— Heparin inhibition of endothelial cell proliferation and organization requires a chain length of >8 saccharide units, with maximal inhibition at M_r of 6 kDa. This M_r dependence differs from that required for anticoagulant activity.

Key Words: low molecular weight heparins • cancer • angiogenesis • endothelium • thrombosis

This article has been cited by other articles:

				A. A. Khorana Cancer and thrombosis: implications of published guidelines for clinical practice Ann. Onc., June 26, 2009; (2009) mdp068v1. [Abstract] [Full Text] [PDF]

				C. L. R. Belmiro, M. T. L. Castelo-Branco, L. M. C. Melim, A. Schanaider, C. Elia, K. Madi, M. S. G. Pavao, and H. S. P. de Souza Unfractionated Heparin and New Heparin Analogues from Ascidians (Chordate-Tunicate) Ameliorate Colitis in Rats J. Biol. Chem., April 24, 2009; 284(17): 11267 - 11278. [Abstract] [Full Text] [PDF]

				C. Adiguzel, W. P. Jeske, D. Hoppensteadt, J. M. Walenga, V. Bansal, and J. Fareed Structural and Functional Characterization of Low-molecular-weight Heparins: Impact on the Development of Guidelines for Generic Products Clinical and Applied Thrombosis/Hemostasis, April 1, 2009; 15(2): 137 - 144. [Abstract] [PDF]

				T. Sousou and A. A. Khorana New Insights Into Cancer-Associated Thrombosis Arterioscler. Thromb. Vasc. Biol., March 1, 2009; 29(3): 316 - 320. [Abstract] [Full Text] [PDF]

				E. Al-Ansari, H.-k. Du, L. Yu, C. D. Ochoa, H. G. Garg, D. A. Quinn, and C. A. Hales Low-Molecular-Weight Heparin Inhibits Hypoxic Pulmonary Hypertension and Vascular Remodeling in Guinea Pigs Chest, December 1, 2007; 132(6): 1898 - 1905. [Abstract] [Full Text] [PDF]

				R. Sakiyama, K. Fukuta, K. Matsumoto, M. Furukawa, Y. Takahashi, and T. Nakamura Stimulation of Hepatocyte Growth Factor Production by Heparin-derived Oligosaccharides J. Biochem., May 1, 2007; 141(5): 653 - 660. [Abstract] [Full Text] [PDF]

				A. A. Khorana, C. W. Francis, E. Culakova, R. I. Fisher, N. M. Kuderer, and G. H. Lyman Thromboembolism in Hospitalized Neutropenic Cancer Patients J. Clin. Oncol., January 20, 2006; 24(3): 484 - 490. [Abstract] [Full Text] [PDF]

				A. Segev, N. Nili, and B. H Strauss The role of perlecan in arterial injury and angiogenesis Cardiovasc Res, September 1, 2004; 63(4): 603 - 610. [Abstract] [Full Text] [PDF]

				J. Rak and J. I. Weitz Heparin and Angiogenesis: Size Matters! Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 1954 - 1955. [Full Text] [PDF]